Triazolopyridine compounds as pim kinase inhibitors

A compound of general Formula I

• and stereoisomers, pharmaceutically acceptable salts and solvates thereof, wherein:
• R1 is H, halogen, CN, OH, (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, hydroxy(1-6C)alkyl, cyano(1-6C)alkyl, (1-3C alkoxy)(1-6C)alkyl (optionally substituted with hydroxy), di(1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy, fluoro(1-6C)alkoxy, difluoro(1-6C)alkoxy, trifluoro(1-6C)alkoxy, hydroxy(2-6C)alkoxy, cyano(1-6C)alkoxy, (1-3C alkoxy)(2-6C)alkoxy, di(1-3C alkoxy)(2-6C)alkoxy, (3-6C cycloalkyl)methoxy, oxetanylmethoxy (optionally substituted with methyl), (1-6C alkyl)sulfanyl, —C(═O)NRaRb, —CH2C(═O)NRcRd, or (3-6C)cycloalkyl optionally substituted with —CH2OH or —CH2O(1-4C alkyl);
• Ra, Rb, Rc and Rd are independently selected from H and (1-4C)alkyl;
• R2 is H, halogen, CN, OH, (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, hydroxy(1-6C)alkyl, (1-3C alkoxy)(1-6C)allyl, (1-6C)alkoxy (optionally substituted with (1-6C alkyl)C(═O)O—, amino(1-6C alkyl)C(═O)O—, or phenyl(C═O)O—), fluoro(1-6C)alkoxy, difluoro(1-6C)alkoxy, trifluoro(1-6C)alkoxy, hydroxy(2-6C)alkoxy, (1-3C alkoxy)(2-6C)alkoxy, (3-6C cycloalkyl)methoxy, (3-6C)cycloalkoxy (optionally substituted with OH), oxetanylmethoxy (optionally substituted with methyl), tetrahydropyranyloxy, (1-6C alkyl)sulfanyl, hydroxy(2-6C alkyl)sulfanyl, (1-3C alkylsulfanyl)(2-6C)alkoxy, —COOH, hetAr1, —C(═O)NReRf, —NReC(═O)Rf, oxetanyl, or cyclopropyl optionally substituted with —CH2OH or —CH2O(1-6C alkyl);
• or R1 and R2 together with the atoms to which they are attached form a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from O and N, wherein said ring is optionally substituted with (1-4C)alkyl;
• hetAr1 is a 5-6 membered heteroaryl ring having one or two ring nitrogen atoms and optionally substituted with one or more groups selected from (1-6C)alkyl;
• Re and Rf are independently H, (1-6C)alkyl or cyclopropyl optionally substituted with (1-4C)alkyl;
• R3 is H, halogen or (1-6C)alkyl;
• R4 is
• R5 is CF3, CH2F, CHF2, methyl or ethyl;
• R5a is H or methyl;
• or R5 and R5a together with the atom to which they are attached form a cyclopropyl ring;
• R6 is H, NH2, OH, (1-6C alkyl)NH—, fluoro(1-6C alkyl)NH—, hydroxy(1-6C alkyl)NH—, (3-6C cycloalkyl)CH2NH—, (1-6C alkyl)C(═O)NH—, (1-6C alkyl)OC(═O)NH— (optionally substituted with 5-methyl-2-oxo-1,3-dioxol-4-yl) or amino(1-6C)alkyl-;
• R7 is H, (1-6C)alkyl, fluoro(1-6C)alkyl or hydroxy(1-6C)alkyl;
• or R6 and R7 together with the atom to which they are attached form a 5-6 membered spirocyclic heterocycle having a ring nitrogen atom;
• R8 is H, halogen, OH, or (1-6C)alkoxy, or
• R6 and R8 together with the carbon atoms to which they are attached form a cyclopropyl ring optionally substituted with NH2;
• R9 is H, or
• R6 and R9 together form a linking group having the formula —CH2NH— which links the carbon atoms to which they are attached;
• and
• R10 is H or halogen.